By Adriano Marchese


GlaxoSmithKline PLC said Friday that the European Commission has granted conditional marketing authorization for Jemperli, a treatment for endometrial cancer.

The British pharmaceutical giant said the approval makes Jemperli, also known as dostarlimab, the first anti-PD-1 therapy available for endometrial cancer in Europe.

The drug is a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer.

"Today's approval of dostarlimab means that for the first time in Europe, these women will have access to a new, innovative and much-needed therapy," Hal Barron, chief scientific officer and president of research and development, said.


Write to Adriano Marchese at


(END) Dow Jones Newswires

April 23, 2021 10:30 ET (14:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.